Table 2.

Statistical analysis of regulation of potential GBM-specific serum biomarkers in different glioma grades

Sl no.GeneCutoff log 2 ratiosNormalDO IIDA IIAO IIIAA IIIGBMPost hoc P*Kruskal-Wallis test
PercentageMean log 2 ratios ± S.DPercentageMean log 2 ratios ± S.DPercentageMean log 2 ratios ± S.DPercentageMean log 2 ratios ± S.DPercentageMean log 2 ratios ± S.DPercentageMean log 2 ratios ± S.Dχ2P
I. GBM upregulated genes
    1CXCL92.5014.28% (1/7)0.00 ± 1.9114.28% (1/7)0.53 ± 2.6450.00% (4/8)2.78 ± 2.3526.92% (7/26)1.28 ± 2.1434.61% (9/26)2.10 ± 2.3084.09% (37/44)3.74 ± 1.94ε = 0.000729.93<0.0001
ω = 0.006
¢ = 0.0002
π = 0.0365
    2TIMP12.0014.20% (1/7)0.00 ± 1.840% (0/7)−2.93 ± 1.350% (0/8)−1.95 ± 1.6111.50% (3/26)−1.54 ± 2.240% (0/26)−2.30 ± 1.2868.10% (30/44)2.36 ± 1.79α = 0.0369.38<0.0001
δ = 0.028
ε = 0.018
ω < 0.0001
λ < 0.0001
¢ < 0.0001
π < 0.0001
    3SERPINE11.0042.80% (3/7)0.00 ± 2.470% (0/7)−3.25 ± 1.410% (0/8)−1.50 ± 1.3923.10% (6/26)−1.29 ± 2.8811.50% (3/26)−1.45 ± 1.6968.10% (30/44)2.09 ± 2.55ω < 0.000152.69<0.0001
λ = 0.0017
¢ < 0.0001
π < 0.0001
    4IL61.0042.80% (3/7)0.00 ± 2.210% (0/7)−1.57 ± 1.330% (0/8)−0.96 ± 1.167.60% (2/26)−1.82 ± 1.487.60% (2/26)−1.05 ± 1.6365.90% (29/44)2.10 ± 2.00ε = 0.042759.62<0.0001
ω < 0.0001
λ = 0.0002
¢ < 0.0001
π < 0.0001
    5CALU0.5642.85% (3/7)0.00 ± 1.440% (0/7)−1.40 ± 0.7825.00% (2/8)−0.06 ± 1.017.69% (2/26)−0.98 ± 0.880% (0/26)−1.20 ± 0.7179.54% (35/44)1.26 ± 1.07δ = 0.043770.04<0.0001
ε = 0.0206
ω < 0.0001
μ = 0.0432
λ = 0.0069
¢ < 0.0001
π < 0.0001
    6PLAT0.5628.57% (2/7)0.00 ± 1.730% (0/7)−3.02 ± 0.8212.50% (1/8)−2.25 ± 1.863.84% (1/26)−2.20 ± 1.673.84% (1/26)−2.40 ± 1.4672.72% (32/44)0.90 ± 1.28α = 0.002764.66<0.0001
β = 0.0426
γ = 0.0079
δ = 0.0027
ω < 0.0001
λ < 0.0001
¢ < 0.0001
π < 0.0001
    7AOPN tv 12.000% (0/4)0.00 ± 1.070% (0/7)−0.86 ± 0.8625.00% (2/8)1.43 ± 0.8319.20% (5/26)0.53 ± 1.877.60% (2/26)0.19 ± 1.2777.20% (34/44)2.97 ± 1.62ε = 0.004154.48<0.0001
η = 0.0488
ω < 0.0001
¢ < 0.0001
π < 0.0001
    7BOPN tv 24.000% (0/4)0.00 ± 1.080% (0/7)1.67 ± 1.0712.50% (1/8)1.59 ± 2.0126.90% (7/26)2.94 ± 1.757.60% (2/26)2.19 ± 1.2497.70% (43/44)6.34 ± 1.36γ = 0.003978.25<0.0001
ε < 0.0001
ω < 0.0001
λ < 0.0001
¢ < 0.0001
π < 0.0001
    7COPN tv 31.0025.00% (1/4)0.00 ± 1.110% (0/7)−1.94 ± 1.420% (0/8)−0.15 ± 0.9015.30% (4/26)−0.30 ± 1.6423.10% (6/26)−0.44 ± 1.8490.90% (40/44)3.32 ± 1.66ε = 0.002467.38<0.0001
ω < 0.0001
λ < 0.0001
¢ < 0.0001
π < 0.0001
II. GBM downregulated genes
    8GPX33.00100% (7/7)0.00 ± 1.6371.42% (5/7)0.99 ± 2.3337.50% (3/8)3.74 ± 1.6180.00% (21/26)2.27 ± 1.3623.07% (6/26)4.02 ± 1.7075.0% (33/44)2.20 ± 1.59β = 0.000334.00<0.0001
γ = 0.0160
δ < 0.0001
ε = 0.0145
η = 0.0170
Φ = 0.0004
ζ = 0.0024
π = 0.0002
    9TIMP3−0.5657.14% (4/7)0.00 ± 1.5771.42% (5/7)−1.22 ± 0.7212.50% (1/8)−0.31 ± 0.5057.69% (15/26)−1.19 ± 1.0538.46% (10/26)−0.60 ± 0.7479.54% (35/44)−1.53 ± 1.04ε = 0.002722.560.0004
λ = 0.0188
π = 0.0073
  • *Tukey's post hoc test showing a significant P value: α, normal vs DO; β, normal vs DA; γ, normal vs AO; δ, normal vs AA; ε, normal vs GBM; η, DO vs DA; Ψ, DO vs AO; Φ, DO vs AO; ω, DO vs GBM; Ω, DA vs AO; μ, DA vs AA; λ, DA vs GBM; ζ, AO vs AA; ¢, AO vs GBM; π, AA vs GBM.

  • *Tukey's post hoc test showing a significant P value: α, normal vs DO; β, normal vs DA; γ, normal vs AO; δ, normal vs AA; ε, normal vs GBM; η, DO vs DA; Ψ, DO vs AO; Φ, DO vs AO; ω, DO vs GBM; Ω, DA vs AO; μ, DA vs AA; λ, DA vs GBM; ζ, AO vs AA; ¢, AO vs GBM; π, AA vs GBM.